Literature DB >> 11004568

Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors.

W R Mann1, C J Dragland, C C Vinluan, T R Vedananda, P A Bell, T D Aicher.   

Abstract

The mechanism of action of structurally distinct pyruvate dehydrogenase kinase (PDK) inhibitors was examined in assays with experimental contexts ranging from an intact pyruvate dehydrogenase complex (PDC) with and without supplemental ATP or ADP to a synthetic peptide substrate to PDK autophosphorylation. Some compounds directly inhibited the catalytic activity of PDKs. Some of the inhibitor classes tested inhibited autophosphorylation of recombinant PDK1 and PDK2. During these studies, PDC was shown to be directly inhibited by a novel mechanism; the addition of supplemental recombinant PDKs, an effect that is ADP-dependent and partly alleviated by members of each of the compound classes tested. Overall, these data demonstrate that small molecules acting at diverse sites can inhibit PDK activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11004568     DOI: 10.1016/s0167-4838(00)00079-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Interaction between the individual isoenzymes of pyruvate dehydrogenase kinase and the inner lipoyl-bearing domain of transacetylase component of pyruvate dehydrogenase complex.

Authors:  Alina Tuganova; Igor Boulatnikov; Kirill M Popov
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

2.  Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site.

Authors:  Tiziana Masini; Barbara Birkaya; Simon van Dijk; Milon Mondal; Johan Hekelaar; Manuel Jäger; Anke C Terwisscha van Scheltinga; Mulchand S Patel; Anna K H Hirsch; Edelmiro Moman
Journal:  J Enzyme Inhib Med Chem       Date:  2016-07-19       Impact factor: 5.051

Review 3.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

Review 4.  Metabolic inertia in contracting skeletal muscle: a novel approach for pharmacological intervention in peripheral vascular disease.

Authors:  P L Greenhaff; S P Campbell-O'Sullivan; D Constantin-Teodosiu; S M Poucher; P A Roberts; J A Timmons
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

Review 5.  Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers.

Authors:  Nam Ho Jeoung
Journal:  Diabetes Metab J       Date:  2015-06       Impact factor: 5.376

6.  Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours.

Authors:  Tereza Golias; Ioanna Papandreou; Ramon Sun; Bhavna Kumar; Nicole V Brown; Benjamin J Swanson; Reetesh Pai; Diego Jaitin; Quynh-Thu Le; Theodoros N Teknos; Nicholas C Denko
Journal:  Sci Rep       Date:  2016-08-08       Impact factor: 4.379

7.  Mitochondrial Utilization of Competing Fuels Is Altered in Insulin Resistant Skeletal Muscle of Non-obese Rats (Goto-Kakizaki).

Authors:  Nicola Lai; Ciarán E Fealy; Chinna M Kummitha; Silvia Cabras; John P Kirwan; Charles L Hoppel
Journal:  Front Physiol       Date:  2020-06-16       Impact factor: 4.566

8.  Dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, ameliorates type 2 diabetes via reduced gluconeogenesis.

Authors:  Yuko Katayama; Yayoi Kawata; Yusuke Moritoh; Masanori Watanabe
Journal:  Heliyon       Date:  2022-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.